Current Report Filing (8-k)
March 18 2022 - 4:08PM
Edgar (US Regulatory)
0001788028
false
0001788028
2022-03-18
2022-03-18
0001788028
JSPR:VotingCommonStockParValue0.0001PerShareMember
2022-03-18
2022-03-18
0001788028
JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member
2022-03-18
2022-03-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 18, 2022
JASPER THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its
Charter)
Delaware |
|
001-39138 |
|
84-2984849 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
2200 Bridge Pkwy Suite #102
Redwood City, California 94065
(Address of Principal Executive Offices) (Zip
Code)
(650) 549-1400
Registrant’s telephone number, including
area code
N/A
(Former Name, or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
(Title of each class) |
|
(Trading Symbol) |
|
(Name of exchange on which registered) |
Voting Common Stock, par value $0.0001 per
share |
|
JSPR |
|
The Nasdaq Stock Market LLC |
Redeemable Warrants, each whole warrant exercisable
for one share of Voting Common Stock at an exercise price of $11.50 |
|
JSPRW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 2.02.
Results of Operations and Financial Condition.
On March 18, 2022, Jasper
Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the full-year ended December
31, 2021 and providing other business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
In accordance with General
Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
JASPER THERAPEUTICS, INC. |
|
|
Date: March 18, 2022 |
By: |
/s/ Jeet Mahal |
|
|
Jeet Mahal |
|
|
Chief Financial Officer, Chief Business
Officer and Corporate Secretary |
2
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From May 2024 to Jun 2024
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From Jun 2023 to Jun 2024